Free Trial

MetLife (MET) Stock Forecast & Price Target

MetLife logo
$78.75 +0.76 (+0.97%)
Closing price 05/29/2025 03:59 PM Eastern
Extended Trading
$78.86 +0.11 (+0.13%)
As of 05/29/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MetLife - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
12

Based on 13 Wall Street analysts who have issued ratings for MetLife in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a hold rating, and 12 have given a buy rating for MET.

Consensus Price Target

$94.17
19.58% Upside
According to the 13 analysts' twelve-month price targets for MetLife, the average price target is $94.17. The highest price target for MET is $99.00, while the lowest price target for MET is $86.00. The average price target represents a forecasted upside of 19.58% from the current price of $78.75.
Get the Latest News and Ratings for MET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MetLife and its competitors.

Sign Up

MET Analyst Ratings Over Time

TypeCurrent Forecast
5/30/24 to 5/30/25
1 Month Ago
4/30/24 to 4/30/25
3 Months Ago
3/1/24 to 3/1/25
1 Year Ago
5/31/23 to 5/30/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
13 Buy rating(s)
11 Buy rating(s)
12 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$94.17$92.46$94.58$79.08
Forecasted Upside19.58% Upside22.84% Upside9.78% Upside11.20% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

MET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MetLife Stock vs. The Competition

TypeMetLifeFinance CompaniesS&P 500
Consensus Rating Score
2.92
2.53
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside19.58% Upside28.47% Upside14.89% Upside
News Sentiment Rating
Positive News

See Recent MET News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/19/2025Morgan Stanley
3 of 5 stars
Nigel Dally
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$94.00 ➝ $99.00+22.51%
5/6/2025Wells Fargo & Company
3 of 5 stars
Elyse Greenspan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$91.00 ➝ $94.00+21.46%
4/11/2025Barclays
3 of 5 stars
Alex Scott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$95.00 ➝ $88.00+23.51%
4/9/2025Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ryan Krueger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$98.00 ➝ $95.00+40.70%
4/2/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brian Meredith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$94.00 ➝ $98.00+19.58%
4/2/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
John Barnidge
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$92.00 ➝ $94.00+14.87%
4/2/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jimmy Bhullar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$88.00 ➝ $86.00+5.94%
3/7/2025Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy
1/23/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jack Matten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$97.00+13.09%
11/27/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Kligerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$97.00 ➝ $99.00+11.50%
9/27/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$89.00 ➝ $95.00+14.71%
8/1/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$99.00 ➝ $96.00+24.92%
7/23/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$83.00 ➝ $89.00+18.26%
5/22/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$77.00 ➝ $80.00+9.50%
1/8/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$70.00 ➝ $80.00+16.08%
10/4/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$71.00+18.33%
8/4/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$70.00 ➝ $74.00+14.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:54 AM ET.


Should I Buy MetLife Stock? MET Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, May 29, 2025. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MetLife
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in MetLife, Inc.:

  • The recent increase in the quarterly dividend to $0.5675 reflects the company's commitment to returning value to shareholders, indicating strong financial health.
  • MetLife, Inc. has initiated a substantial stock repurchase plan of $3.00 billion, suggesting that the management believes the stock is undervalued, which can enhance shareholder value.
  • The company reported a revenue increase of 15.6% year-over-year, showcasing robust growth and operational efficiency.
  • With a current stock price around $94, analysts have a consensus target price of approximately $94.17, indicating potential for price appreciation.
  • MetLife, Inc. maintains a healthy return on equity of 20.42%, which is a strong indicator of effective management and profitability.

MetLife
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in MetLife, Inc. for these reasons:

  • The company missed earnings estimates by $0.04, which may raise concerns about its ability to meet future financial targets.
  • MetLife, Inc. has a quick ratio of 0.16, indicating potential liquidity issues, as it suggests the company may struggle to cover short-term liabilities.
  • The debt-to-equity ratio of 0.54, while manageable, indicates that the company is somewhat reliant on debt financing, which could pose risks in a rising interest rate environment.
  • Despite the positive revenue growth, the net margin of 6.19% suggests that profitability may be under pressure, which could affect future earnings.
  • Market analysts have mixed ratings, with some holding a "hold" rating, indicating uncertainty about the stock's future performance.

MET Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for MetLife is $94.17, with a high forecast of $99.00 and a low forecast of $86.00.

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MetLife in the last twelve months. There is currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MET shares.

According to analysts, MetLife's stock has a predicted upside of 19.58% based on their 12-month stock forecasts.

MetLife has been rated by research analysts at Barclays, Cowen, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Morgan Stanley, Piper Sandler, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like MetLife more than other "finance" companies. The consensus rating score for MetLife is 2.92 while the average consensus rating score for "finance" companies is 2.53. Learn more on how MET compares to other companies.


This page (NYSE:MET) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners